Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Peripheral Arterial Disease | 86 | 2024 | 1271 | 21.910 |
Why?
|
Platelet Aggregation Inhibitors | 74 | 2024 | 2746 | 8.430 |
Why?
|
Myocardial Infarction | 88 | 2024 | 11458 | 6.440 |
Why?
|
Lactones | 24 | 2022 | 316 | 5.650 |
Why?
|
Purinergic P2Y Receptor Antagonists | 26 | 2024 | 284 | 5.260 |
Why?
|
Adenosine | 20 | 2023 | 805 | 4.630 |
Why?
|
Lower Extremity | 25 | 2024 | 1200 | 4.470 |
Why?
|
Aspirin | 32 | 2024 | 3127 | 4.400 |
Why?
|
Secondary Prevention | 42 | 2024 | 1470 | 4.100 |
Why?
|
Vascular Surgical Procedures | 14 | 2024 | 1489 | 3.530 |
Why?
|
Acute Coronary Syndrome | 34 | 2024 | 2190 | 3.480 |
Why?
|
Ischemia | 26 | 2024 | 1885 | 3.380 |
Why?
|
Fibrinolytic Agents | 16 | 2024 | 2073 | 3.350 |
Why?
|
Pyridines | 27 | 2022 | 2875 | 3.250 |
Why?
|
Thrombosis | 21 | 2024 | 2942 | 2.920 |
Why?
|
Stroke | 41 | 2024 | 9715 | 2.770 |
Why?
|
Hemorrhage | 42 | 2024 | 3418 | 2.570 |
Why?
|
Endovascular Procedures | 12 | 2024 | 2182 | 2.350 |
Why?
|
Troponin I | 10 | 2022 | 650 | 2.350 |
Why?
|
Atherosclerosis | 21 | 2024 | 3400 | 2.220 |
Why?
|
Drug Therapy, Combination | 27 | 2024 | 6305 | 2.120 |
Why?
|
Aortic Diseases | 5 | 2022 | 735 | 1.970 |
Why?
|
Anticholesteremic Agents | 7 | 2024 | 967 | 1.950 |
Why?
|
Hydroxymethylglutaryl-CoA Reductase Inhibitors | 14 | 2024 | 3245 | 1.790 |
Why?
|
Receptor, PAR-1 | 10 | 2019 | 109 | 1.720 |
Why?
|
Treatment Outcome | 91 | 2024 | 64572 | 1.510 |
Why?
|
Diabetes Mellitus, Type 2 | 23 | 2024 | 12143 | 1.460 |
Why?
|
Venous Thromboembolism | 11 | 2023 | 1866 | 1.460 |
Why?
|
Drug-Eluting Stents | 4 | 2023 | 681 | 1.440 |
Why?
|
Thrombolytic Therapy | 8 | 2021 | 2055 | 1.380 |
Why?
|
Coronary Artery Disease | 15 | 2024 | 6403 | 1.330 |
Why?
|
Dyslipidemias | 4 | 2021 | 868 | 1.330 |
Why?
|
Brain Ischemia | 8 | 2022 | 3030 | 1.320 |
Why?
|
Blood Coagulation Disorders | 2 | 2023 | 350 | 1.290 |
Why?
|
Cardiovascular Diseases | 29 | 2024 | 15498 | 1.230 |
Why?
|
Humans | 256 | 2024 | 760740 | 1.230 |
Why?
|
Glucosides | 8 | 2020 | 512 | 1.220 |
Why?
|
Cholesterol, LDL | 7 | 2024 | 2378 | 1.170 |
Why?
|
Renal Insufficiency, Chronic | 5 | 2022 | 2252 | 1.120 |
Why?
|
Double-Blind Method | 43 | 2024 | 12333 | 1.110 |
Why?
|
Embolism | 2 | 2022 | 399 | 1.070 |
Why?
|
Receptors, Thrombin | 5 | 2015 | 130 | 1.060 |
Why?
|
Benzhydryl Compounds | 8 | 2020 | 915 | 1.050 |
Why?
|
Risk Factors | 72 | 2024 | 74128 | 1.040 |
Why?
|
Aged | 121 | 2024 | 169092 | 1.040 |
Why?
|
Phosphatidylcholine-Sterol O-Acyltransferase | 2 | 2022 | 33 | 1.020 |
Why?
|
Sterol O-Acyltransferase | 2 | 2022 | 28 | 1.020 |
Why?
|
Diabetes Mellitus | 11 | 2023 | 5838 | 1.010 |
Why?
|
Coronary Thrombosis | 4 | 2018 | 440 | 1.000 |
Why?
|
Hypolipidemic Agents | 2 | 2021 | 609 | 0.980 |
Why?
|
Anticoagulants | 15 | 2024 | 4785 | 0.950 |
Why?
|
Troponin T | 6 | 2022 | 780 | 0.930 |
Why?
|
Extremities | 6 | 2021 | 867 | 0.900 |
Why?
|
Risk Assessment | 32 | 2024 | 23974 | 0.880 |
Why?
|
Randomized Controlled Trials as Topic | 21 | 2024 | 10203 | 0.880 |
Why?
|
Middle Aged | 107 | 2024 | 220603 | 0.850 |
Why?
|
Male | 133 | 2024 | 360402 | 0.830 |
Why?
|
Anterior Wall Myocardial Infarction | 1 | 2022 | 42 | 0.800 |
Why?
|
Fibrin Fibrinogen Degradation Products | 2 | 2023 | 426 | 0.780 |
Why?
|
Female | 131 | 2024 | 392203 | 0.780 |
Why?
|
Walking | 5 | 2022 | 1197 | 0.770 |
Why?
|
Acetanilides | 6 | 2014 | 169 | 0.760 |
Why?
|
Limb Salvage | 6 | 2024 | 480 | 0.750 |
Why?
|
Heart Failure | 15 | 2023 | 11670 | 0.740 |
Why?
|
Beneficence | 1 | 2021 | 54 | 0.730 |
Why?
|
Cardiovascular Agents | 4 | 2022 | 840 | 0.720 |
Why?
|
Vascular Diseases | 4 | 2023 | 1159 | 0.700 |
Why?
|
Serine Proteinase Inhibitors | 2 | 2020 | 175 | 0.690 |
Why?
|
Antifibrinolytic Agents | 1 | 2023 | 287 | 0.680 |
Why?
|
Hypercholesterolemia | 2 | 2024 | 1141 | 0.640 |
Why?
|
Atrial Fibrillation | 5 | 2024 | 5031 | 0.640 |
Why?
|
Research Subjects | 1 | 2021 | 249 | 0.630 |
Why?
|
Piperazines | 8 | 2014 | 2521 | 0.630 |
Why?
|
Personal Autonomy | 1 | 2021 | 304 | 0.610 |
Why?
|
Platelet Aggregation | 5 | 2023 | 771 | 0.590 |
Why?
|
Kaplan-Meier Estimate | 16 | 2024 | 6473 | 0.580 |
Why?
|
Outpatients | 3 | 2024 | 1596 | 0.580 |
Why?
|
Kidney Diseases | 5 | 2020 | 2090 | 0.570 |
Why?
|
Chest Pain | 4 | 2017 | 1091 | 0.560 |
Why?
|
Time Factors | 33 | 2024 | 39908 | 0.550 |
Why?
|
Renal Insufficiency | 2 | 2021 | 808 | 0.530 |
Why?
|
Leg | 1 | 2021 | 1087 | 0.530 |
Why?
|
Myocardial Ischemia | 6 | 2021 | 2110 | 0.520 |
Why?
|
Follow-Up Studies | 27 | 2022 | 39062 | 0.510 |
Why?
|
Growth Differentiation Factor 15 | 3 | 2023 | 197 | 0.510 |
Why?
|
Electrocardiography | 8 | 2018 | 6346 | 0.510 |
Why?
|
Acute Disease | 8 | 2021 | 7236 | 0.500 |
Why?
|
Caffeine | 1 | 2020 | 699 | 0.500 |
Why?
|
Lipoproteins, HDL | 4 | 2024 | 675 | 0.500 |
Why?
|
Intermittent Claudication | 4 | 2022 | 304 | 0.490 |
Why?
|
Cardiology | 3 | 2022 | 1656 | 0.490 |
Why?
|
Diabetes Complications | 2 | 2021 | 1315 | 0.490 |
Why?
|
Paclitaxel | 2 | 2021 | 1730 | 0.480 |
Why?
|
Cerebrovascular Disorders | 2 | 2018 | 1474 | 0.480 |
Why?
|
Dyspnea | 2 | 2020 | 1347 | 0.470 |
Why?
|
Beverages | 1 | 2020 | 821 | 0.470 |
Why?
|
Sex Characteristics | 2 | 2023 | 2637 | 0.470 |
Why?
|
Patient Selection | 3 | 2022 | 4237 | 0.470 |
Why?
|
Myocarditis | 2 | 2019 | 788 | 0.460 |
Why?
|
Informed Consent | 1 | 2021 | 1007 | 0.460 |
Why?
|
Hypoglycemic Agents | 10 | 2024 | 3085 | 0.450 |
Why?
|
Ulcer | 2 | 2021 | 203 | 0.450 |
Why?
|
Aortic Aneurysm, Thoracic | 1 | 2020 | 696 | 0.450 |
Why?
|
Ventricular Function, Left | 3 | 2023 | 3873 | 0.440 |
Why?
|
Syndrome | 5 | 2023 | 3268 | 0.430 |
Why?
|
Hospitalization | 9 | 2023 | 10708 | 0.420 |
Why?
|
Patient Care Team | 1 | 2024 | 2515 | 0.420 |
Why?
|
Recurrence | 20 | 2024 | 8426 | 0.420 |
Why?
|
Lecithins | 2 | 2022 | 17 | 0.420 |
Why?
|
Cholesterol | 4 | 2022 | 2902 | 0.420 |
Why?
|
Apolipoprotein A-I | 2 | 2024 | 299 | 0.410 |
Why?
|
Diabetic Cardiomyopathies | 3 | 2019 | 90 | 0.410 |
Why?
|
Benzazepines | 3 | 2019 | 310 | 0.400 |
Why?
|
Pregnancy-Associated Plasma Protein-A | 1 | 2012 | 60 | 0.400 |
Why?
|
Incidence | 15 | 2024 | 21339 | 0.390 |
Why?
|
Consensus | 2 | 2022 | 3117 | 0.390 |
Why?
|
Databases, Factual | 5 | 2024 | 7963 | 0.370 |
Why?
|
Stents | 4 | 2021 | 3177 | 0.360 |
Why?
|
Heparin | 3 | 2023 | 1632 | 0.360 |
Why?
|
Drug Administration Schedule | 9 | 2024 | 4845 | 0.360 |
Why?
|
Blood Platelets | 5 | 2023 | 2478 | 0.350 |
Why?
|
Disease Management | 1 | 2021 | 2506 | 0.350 |
Why?
|
Hematoma | 2 | 2021 | 762 | 0.350 |
Why?
|
Thiophenes | 2 | 2011 | 569 | 0.350 |
Why?
|
Natriuretic Peptide, Brain | 5 | 2023 | 1723 | 0.340 |
Why?
|
Dose-Response Relationship, Drug | 10 | 2021 | 10754 | 0.340 |
Why?
|
Postoperative Complications | 2 | 2021 | 15609 | 0.320 |
Why?
|
Enoxaparin | 2 | 2021 | 391 | 0.320 |
Why?
|
Death, Sudden, Cardiac | 3 | 2018 | 1551 | 0.320 |
Why?
|
Thrombin | 3 | 2021 | 592 | 0.320 |
Why?
|
Smoking Cessation | 2 | 2024 | 2056 | 0.320 |
Why?
|
Medicare | 9 | 2024 | 6774 | 0.310 |
Why?
|
Enzyme Inhibitors | 5 | 2014 | 3705 | 0.310 |
Why?
|
Cause of Death | 8 | 2024 | 3683 | 0.310 |
Why?
|
Appetite Depressants | 2 | 2019 | 108 | 0.300 |
Why?
|
Prognosis | 15 | 2024 | 29601 | 0.300 |
Why?
|
Multicenter Studies as Topic | 5 | 2021 | 1700 | 0.290 |
Why?
|
Prospective Studies | 20 | 2022 | 54364 | 0.290 |
Why?
|
Medical Oncology | 1 | 2019 | 2317 | 0.290 |
Why?
|
Intracranial Hemorrhages | 5 | 2018 | 809 | 0.280 |
Why?
|
Survival Rate | 6 | 2021 | 12719 | 0.280 |
Why?
|
Factor XI | 2 | 2024 | 34 | 0.280 |
Why?
|
Patient Readmission | 1 | 2021 | 3269 | 0.280 |
Why?
|
Diabetes Mellitus, Experimental | 2 | 2023 | 1117 | 0.270 |
Why?
|
Ovarian Neoplasms | 1 | 2023 | 4849 | 0.270 |
Why?
|
Angina Pectoris | 2 | 2009 | 959 | 0.270 |
Why?
|
Diagnostic Imaging | 1 | 2020 | 3527 | 0.270 |
Why?
|
Proportional Hazards Models | 11 | 2021 | 12448 | 0.260 |
Why?
|
United States | 20 | 2024 | 72292 | 0.250 |
Why?
|
Clinical Trials, Phase III as Topic | 5 | 2021 | 857 | 0.250 |
Why?
|
Signal Processing, Computer-Assisted | 1 | 2012 | 1493 | 0.240 |
Why?
|
Ventricular Function | 1 | 2006 | 406 | 0.240 |
Why?
|
Troponin | 3 | 2020 | 502 | 0.230 |
Why?
|
Popliteal Artery | 2 | 2023 | 310 | 0.230 |
Why?
|
American Heart Association | 3 | 2022 | 1039 | 0.230 |
Why?
|
Ankle Brachial Index | 4 | 2022 | 163 | 0.230 |
Why?
|
Antibodies, Monoclonal | 2 | 2018 | 9171 | 0.230 |
Why?
|
Dipeptidyl-Peptidase IV Inhibitors | 2 | 2018 | 311 | 0.220 |
Why?
|
Angioplasty, Balloon, Coronary | 2 | 2009 | 1723 | 0.220 |
Why?
|
Life Style | 1 | 2015 | 3907 | 0.220 |
Why?
|
Heparin, Low-Molecular-Weight | 2 | 2023 | 344 | 0.210 |
Why?
|
Ticlopidine | 5 | 2016 | 730 | 0.210 |
Why?
|
Exercise | 2 | 2021 | 5886 | 0.210 |
Why?
|
Hypertension | 2 | 2022 | 8532 | 0.210 |
Why?
|
Neoplasms | 3 | 2023 | 22131 | 0.210 |
Why?
|
Thromboembolism | 3 | 2024 | 991 | 0.210 |
Why?
|
MicroRNAs | 3 | 2023 | 3802 | 0.210 |
Why?
|
Quality of Life | 2 | 2022 | 13359 | 0.210 |
Why?
|
Pravastatin | 2 | 2016 | 392 | 0.200 |
Why?
|
Angioplasty, Balloon | 3 | 2023 | 589 | 0.200 |
Why?
|
Heptanoic Acids | 2 | 2015 | 344 | 0.190 |
Why?
|
Europe | 3 | 2021 | 3415 | 0.190 |
Why?
|
Diabetic Nephropathies | 2 | 2019 | 972 | 0.190 |
Why?
|
Aged, 80 and over | 14 | 2024 | 58919 | 0.190 |
Why?
|
Glomerular Filtration Rate | 3 | 2019 | 2174 | 0.190 |
Why?
|
Thromboplastin | 1 | 2023 | 286 | 0.190 |
Why?
|
Internationality | 3 | 2022 | 1000 | 0.190 |
Why?
|
Stroke Volume | 4 | 2023 | 5486 | 0.180 |
Why?
|
Early Termination of Clinical Trials | 1 | 2021 | 67 | 0.180 |
Why?
|
Angioplasty | 1 | 2023 | 355 | 0.180 |
Why?
|
Coronary Artery Bypass | 3 | 2016 | 2188 | 0.180 |
Why?
|
Glucagon-Like Peptides | 1 | 2022 | 153 | 0.180 |
Why?
|
Aortic Aneurysm | 2 | 2016 | 648 | 0.180 |
Why?
|
Arteries | 2 | 2022 | 1120 | 0.170 |
Why?
|
Angiography | 2 | 2024 | 1595 | 0.170 |
Why?
|
Cohort Studies | 10 | 2022 | 41464 | 0.160 |
Why?
|
Angina, Unstable | 3 | 2013 | 888 | 0.160 |
Why?
|
Symporters | 1 | 2022 | 363 | 0.160 |
Why?
|
Methylamines | 1 | 2020 | 136 | 0.160 |
Why?
|
Serotonin 5-HT2 Receptor Agonists | 1 | 2019 | 31 | 0.160 |
Why?
|
Appetite Regulation | 1 | 2019 | 84 | 0.160 |
Why?
|
Hospital Mortality | 3 | 2021 | 5292 | 0.150 |
Why?
|
Pyridones | 1 | 2024 | 808 | 0.150 |
Why?
|
Risk | 5 | 2019 | 9603 | 0.150 |
Why?
|
Tomography, X-Ray Computed | 1 | 2021 | 20556 | 0.150 |
Why?
|
Cardiovascular System | 2 | 2022 | 834 | 0.150 |
Why?
|
Mobility Limitation | 1 | 2022 | 408 | 0.150 |
Why?
|
Combined Modality Therapy | 4 | 2020 | 8516 | 0.150 |
Why?
|
Polyethylene Glycols | 1 | 2023 | 1182 | 0.150 |
Why?
|
Drug Therapy | 1 | 2021 | 503 | 0.150 |
Why?
|
Antineoplastic Agents, Phytogenic | 1 | 2021 | 620 | 0.150 |
Why?
|
Exercise Therapy | 3 | 2022 | 929 | 0.140 |
Why?
|
Adamantane | 1 | 2018 | 148 | 0.140 |
Why?
|
Pyrroles | 2 | 2015 | 1125 | 0.140 |
Why?
|
Myocardial Revascularization | 4 | 2021 | 790 | 0.140 |
Why?
|
Registries | 6 | 2024 | 8209 | 0.140 |
Why?
|
Clinical Trials as Topic | 4 | 2021 | 7995 | 0.140 |
Why?
|
Clinical Chemistry Tests | 2 | 2015 | 59 | 0.140 |
Why?
|
Doxorubicin | 1 | 2023 | 2224 | 0.140 |
Why?
|
Tissue Plasminogen Activator | 1 | 2022 | 1163 | 0.140 |
Why?
|
Peptide Fragments | 2 | 2023 | 5109 | 0.140 |
Why?
|
Dipeptides | 1 | 2018 | 391 | 0.130 |
Why?
|
Placebos | 1 | 2021 | 1667 | 0.130 |
Why?
|
Osteoporosis, Postmenopausal | 1 | 2019 | 396 | 0.130 |
Why?
|
Obesity | 4 | 2019 | 12934 | 0.130 |
Why?
|
Platelet Glycoprotein GPIIb-IIIa Complex | 2 | 2009 | 577 | 0.130 |
Why?
|
Glycopeptides | 2 | 2014 | 220 | 0.130 |
Why?
|
Uracil | 1 | 2017 | 207 | 0.130 |
Why?
|
Peripheral Vascular Diseases | 1 | 2018 | 488 | 0.130 |
Why?
|
Blood Coagulation | 1 | 2021 | 1154 | 0.130 |
Why?
|
Aortitis | 1 | 2016 | 74 | 0.120 |
Why?
|
Platelet Activation | 2 | 2017 | 646 | 0.120 |
Why?
|
Adult | 20 | 2024 | 220995 | 0.120 |
Why?
|
Calibration | 1 | 2018 | 817 | 0.120 |
Why?
|
Lipoprotein(a) | 1 | 2020 | 479 | 0.120 |
Why?
|
Hemoglobins | 1 | 2021 | 1524 | 0.120 |
Why?
|
Thiazoles | 1 | 2022 | 1517 | 0.120 |
Why?
|
Anti-Obesity Agents | 1 | 2018 | 227 | 0.120 |
Why?
|
Adverse Drug Reaction Reporting Systems | 1 | 2018 | 494 | 0.120 |
Why?
|
Research Personnel | 1 | 2020 | 588 | 0.120 |
Why?
|
Pericarditis | 1 | 2016 | 134 | 0.120 |
Why?
|
Benzaldehydes | 1 | 2014 | 59 | 0.120 |
Why?
|
Biphenyl Compounds | 1 | 2019 | 1007 | 0.120 |
Why?
|
Venous Thrombosis | 2 | 2024 | 1303 | 0.120 |
Why?
|
Cyclopropanes | 1 | 2016 | 432 | 0.120 |
Why?
|
Comorbidity | 3 | 2020 | 10507 | 0.120 |
Why?
|
Microcirculation | 1 | 2019 | 1272 | 0.120 |
Why?
|
Vascular Grafting | 1 | 2016 | 162 | 0.120 |
Why?
|
Severity of Illness Index | 3 | 2018 | 15829 | 0.110 |
Why?
|
Kidney | 2 | 2020 | 7044 | 0.110 |
Why?
|
Patient Education as Topic | 1 | 2024 | 2315 | 0.110 |
Why?
|
Biological Assay | 2 | 2015 | 626 | 0.110 |
Why?
|
Warfarin | 1 | 2022 | 1477 | 0.110 |
Why?
|
Marketing | 1 | 2016 | 220 | 0.110 |
Why?
|
Blood Vessel Prosthesis Implantation | 1 | 2023 | 1426 | 0.110 |
Why?
|
France | 3 | 2019 | 492 | 0.110 |
Why?
|
Vascular Patency | 1 | 2016 | 911 | 0.110 |
Why?
|
Pharmaceutical Preparations | 1 | 2021 | 1086 | 0.110 |
Why?
|
Immunotherapy | 2 | 2019 | 4642 | 0.110 |
Why?
|
Ischemic Attack, Transient | 2 | 2015 | 874 | 0.110 |
Why?
|
Retrospective Studies | 8 | 2024 | 80583 | 0.110 |
Why?
|
Oximes | 1 | 2014 | 303 | 0.110 |
Why?
|
p38 Mitogen-Activated Protein Kinases | 1 | 2016 | 682 | 0.110 |
Why?
|
Inflammation | 3 | 2023 | 10759 | 0.100 |
Why?
|
Weight Loss | 3 | 2019 | 2682 | 0.100 |
Why?
|
Diabetic Angiopathies | 1 | 2018 | 803 | 0.100 |
Why?
|
Simvastatin | 1 | 2015 | 346 | 0.100 |
Why?
|
Morbidity | 1 | 2018 | 1750 | 0.100 |
Why?
|
Hyperglycemia | 1 | 2021 | 1375 | 0.100 |
Why?
|
Coronary Angiography | 1 | 2024 | 4470 | 0.100 |
Why?
|
Bone Density Conservation Agents | 1 | 2019 | 794 | 0.100 |
Why?
|
Drug Approval | 2 | 2019 | 812 | 0.100 |
Why?
|
Calgranulin A | 1 | 2012 | 80 | 0.100 |
Why?
|
Calgranulin B | 1 | 2012 | 86 | 0.100 |
Why?
|
Sensitivity and Specificity | 4 | 2014 | 14649 | 0.100 |
Why?
|
Sleep Apnea Syndromes | 1 | 2020 | 978 | 0.100 |
Why?
|
Exercise Tolerance | 1 | 2017 | 836 | 0.100 |
Why?
|
Fatty Acid-Binding Proteins | 1 | 2013 | 295 | 0.100 |
Why?
|
Uncertainty | 1 | 2016 | 752 | 0.100 |
Why?
|
Aortic Valve Stenosis | 1 | 2024 | 2003 | 0.100 |
Why?
|
Age Factors | 4 | 2024 | 18381 | 0.090 |
Why?
|
Osteoprotegerin | 1 | 2012 | 176 | 0.090 |
Why?
|
Pregnancy Proteins | 1 | 2012 | 222 | 0.090 |
Why?
|
Veterans | 2 | 2022 | 2649 | 0.090 |
Why?
|
Hypoglycemia | 1 | 2018 | 883 | 0.090 |
Why?
|
Adiponectin | 1 | 2017 | 1107 | 0.090 |
Why?
|
Intestines | 1 | 2020 | 1909 | 0.090 |
Why?
|
Heart Diseases | 2 | 2016 | 2778 | 0.090 |
Why?
|
Predictive Value of Tests | 5 | 2018 | 15250 | 0.090 |
Why?
|
Reoperation | 1 | 2021 | 4300 | 0.090 |
Why?
|
Overweight | 2 | 2018 | 2417 | 0.090 |
Why?
|
Survival Analysis | 2 | 2014 | 10072 | 0.090 |
Why?
|
Down-Regulation | 1 | 2017 | 2916 | 0.090 |
Why?
|
Guideline Adherence | 1 | 2020 | 2218 | 0.090 |
Why?
|
Inpatients | 1 | 2021 | 2545 | 0.090 |
Why?
|
Heart | 1 | 2023 | 4403 | 0.090 |
Why?
|
Subclavian Steal Syndrome | 1 | 2009 | 20 | 0.080 |
Why?
|
Reproducibility of Results | 4 | 2023 | 20077 | 0.080 |
Why?
|
Infusions, Intravenous | 2 | 2024 | 2214 | 0.080 |
Why?
|
Blood Proteins | 1 | 2014 | 1172 | 0.080 |
Why?
|
Bacteria | 1 | 2020 | 2192 | 0.080 |
Why?
|
ROC Curve | 2 | 2014 | 3575 | 0.080 |
Why?
|
Troponin C | 1 | 2008 | 23 | 0.080 |
Why?
|
International Cooperation | 2 | 2013 | 1422 | 0.080 |
Why?
|
Decision Support Techniques | 1 | 2018 | 1999 | 0.080 |
Why?
|
Piperidines | 1 | 2017 | 1655 | 0.080 |
Why?
|
Obesity, Abdominal | 1 | 2011 | 373 | 0.080 |
Why?
|
Healthcare Disparities | 1 | 2023 | 3351 | 0.070 |
Why?
|
Health Care Costs | 1 | 2021 | 3238 | 0.070 |
Why?
|
Femoral Artery | 2 | 2022 | 826 | 0.070 |
Why?
|
Protein Precursors | 2 | 2014 | 1131 | 0.070 |
Why?
|
Natriuretic Peptides | 1 | 2008 | 155 | 0.070 |
Why?
|
Smoking | 2 | 2021 | 9054 | 0.070 |
Why?
|
Carcinoma, Renal Cell | 1 | 2022 | 3164 | 0.070 |
Why?
|
Coronary Disease | 2 | 2018 | 5911 | 0.070 |
Why?
|
Platelet Function Tests | 2 | 2018 | 271 | 0.070 |
Why?
|
Young Adult | 5 | 2022 | 59191 | 0.060 |
Why?
|
Emergency Service, Hospital | 3 | 2017 | 7873 | 0.060 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 2 | 2023 | 11735 | 0.060 |
Why?
|
Neovascularization, Physiologic | 2 | 2023 | 1349 | 0.060 |
Why?
|
Pandemics | 2 | 2022 | 8652 | 0.060 |
Why?
|
Kidney Neoplasms | 1 | 2022 | 4252 | 0.060 |
Why?
|
Periodicals as Topic | 1 | 2016 | 1463 | 0.060 |
Why?
|
Chi-Square Distribution | 1 | 2010 | 3410 | 0.060 |
Why?
|
Biomedical Research | 1 | 2020 | 3426 | 0.060 |
Why?
|
Sleep | 1 | 2020 | 4764 | 0.060 |
Why?
|
Gangrene | 1 | 2024 | 91 | 0.060 |
Why?
|
Internet | 1 | 2016 | 3094 | 0.060 |
Why?
|
C-Reactive Protein | 2 | 2016 | 3820 | 0.050 |
Why?
|
Mental Disorders | 1 | 2023 | 6826 | 0.050 |
Why?
|
Death | 2 | 2020 | 674 | 0.050 |
Why?
|
Bayes Theorem | 2 | 2023 | 2327 | 0.050 |
Why?
|
Inhibins | 1 | 2023 | 210 | 0.050 |
Why?
|
Child, Preschool | 2 | 2022 | 42193 | 0.050 |
Why?
|
Algorithms | 2 | 2020 | 14024 | 0.050 |
Why?
|
Models, Biological | 1 | 2018 | 9461 | 0.050 |
Why?
|
Receptors, Cell Surface | 1 | 2011 | 2802 | 0.050 |
Why?
|
Adolescent | 4 | 2023 | 88247 | 0.050 |
Why?
|
Internship and Residency | 1 | 2022 | 5878 | 0.050 |
Why?
|
Prevalence | 4 | 2019 | 15702 | 0.050 |
Why?
|
Therapeutics | 1 | 2022 | 113 | 0.050 |
Why?
|
Genome-Wide Association Study | 1 | 2020 | 12661 | 0.050 |
Why?
|
Absorbable Implants | 1 | 2023 | 338 | 0.050 |
Why?
|
Emergency Medical Services | 1 | 2012 | 1921 | 0.040 |
Why?
|
Electronic Health Records | 1 | 2018 | 4810 | 0.040 |
Why?
|
Body Weight | 2 | 2023 | 4615 | 0.040 |
Why?
|
Endothelial Cells | 2 | 2023 | 3550 | 0.040 |
Why?
|
Protein Kinase Inhibitors | 1 | 2016 | 5672 | 0.040 |
Why?
|
Kruppel-Like Transcription Factors | 1 | 2022 | 504 | 0.040 |
Why?
|
Coated Materials, Biocompatible | 1 | 2021 | 311 | 0.040 |
Why?
|
Multivariate Analysis | 1 | 2012 | 12043 | 0.040 |
Why?
|
Necrosis | 1 | 2023 | 1610 | 0.040 |
Why?
|
Heart Ventricles | 1 | 2010 | 3796 | 0.040 |
Why?
|
Coronary Stenosis | 1 | 2024 | 794 | 0.040 |
Why?
|
Diuresis | 1 | 2018 | 106 | 0.040 |
Why?
|
Recovery of Function | 2 | 2019 | 2977 | 0.040 |
Why?
|
New Zealand | 1 | 2018 | 358 | 0.040 |
Why?
|
Patient Discharge | 1 | 2010 | 3442 | 0.040 |
Why?
|
Child | 2 | 2022 | 80089 | 0.040 |
Why?
|
Drug Labeling | 1 | 2019 | 248 | 0.040 |
Why?
|
Tissue Scaffolds | 1 | 2023 | 932 | 0.030 |
Why?
|
Pregnancy | 2 | 2024 | 29869 | 0.030 |
Why?
|
Sodium | 1 | 2022 | 1588 | 0.030 |
Why?
|
Receptors, Purinergic P2Y12 | 1 | 2017 | 115 | 0.030 |
Why?
|
Body Mass Index | 3 | 2023 | 12942 | 0.030 |
Why?
|
Republic of Korea | 1 | 2018 | 583 | 0.030 |
Why?
|
Clinical Trials, Phase II as Topic | 1 | 2018 | 629 | 0.030 |
Why?
|
England | 1 | 2017 | 526 | 0.030 |
Why?
|
Florida | 1 | 2017 | 429 | 0.030 |
Why?
|
Advisory Committees | 1 | 2020 | 787 | 0.030 |
Why?
|
Research Support as Topic | 1 | 2020 | 697 | 0.030 |
Why?
|
Transforming Growth Factor beta | 1 | 2023 | 1962 | 0.030 |
Why?
|
Diet, Reducing | 1 | 2019 | 485 | 0.030 |
Why?
|
Sweden | 1 | 2018 | 1379 | 0.030 |
Why?
|
Osteoporotic Fractures | 1 | 2019 | 410 | 0.030 |
Why?
|
Cost-Benefit Analysis | 2 | 2018 | 5493 | 0.030 |
Why?
|
Marfan Syndrome | 1 | 2016 | 236 | 0.030 |
Why?
|
RNA, Small Interfering | 1 | 2023 | 3419 | 0.030 |
Why?
|
Aortic Valve Insufficiency | 1 | 2018 | 576 | 0.030 |
Why?
|
NF-kappa B | 1 | 2022 | 2481 | 0.030 |
Why?
|
Aorta | 1 | 2021 | 2041 | 0.030 |
Why?
|
Sex Factors | 2 | 2021 | 10549 | 0.030 |
Why?
|
Evidence-Based Medicine | 2 | 2017 | 3680 | 0.030 |
Why?
|
Peripheral Nervous System Diseases | 1 | 2019 | 709 | 0.030 |
Why?
|
Case-Control Studies | 2 | 2022 | 22153 | 0.030 |
Why?
|
Retinal Diseases | 1 | 2019 | 704 | 0.030 |
Why?
|
Sodium Channel Blockers | 1 | 2014 | 172 | 0.030 |
Why?
|
Cerebral Infarction | 1 | 2018 | 980 | 0.030 |
Why?
|
Spinal Fractures | 1 | 2019 | 704 | 0.030 |
Why?
|
Atrial Natriuretic Factor | 1 | 2014 | 350 | 0.030 |
Why?
|
Insulin | 2 | 2018 | 6593 | 0.030 |
Why?
|
Adrenergic beta-Antagonists | 1 | 2018 | 1241 | 0.030 |
Why?
|
Remission Induction | 1 | 2018 | 2391 | 0.030 |
Why?
|
Limit of Detection | 1 | 2013 | 273 | 0.030 |
Why?
|
Prediabetic State | 1 | 2018 | 545 | 0.030 |
Why?
|
Plaque, Atherosclerotic | 1 | 2024 | 1533 | 0.030 |
Why?
|
Disease Susceptibility | 1 | 2019 | 1788 | 0.030 |
Why?
|
Risk Reduction Behavior | 1 | 2019 | 1110 | 0.030 |
Why?
|
Pregnancy Complications, Infectious | 1 | 2024 | 2149 | 0.020 |
Why?
|
Angiotensin Receptor Antagonists | 1 | 2018 | 1040 | 0.020 |
Why?
|
Animals | 5 | 2023 | 168202 | 0.020 |
Why?
|
Disease Progression | 2 | 2019 | 13495 | 0.020 |
Why?
|
Angiotensin-Converting Enzyme Inhibitors | 1 | 2018 | 1517 | 0.020 |
Why?
|
Drug Monitoring | 1 | 2018 | 960 | 0.020 |
Why?
|
Microfilament Proteins | 1 | 2017 | 1130 | 0.020 |
Why?
|
Mice | 3 | 2023 | 81368 | 0.020 |
Why?
|
Hip Fractures | 1 | 2019 | 988 | 0.020 |
Why?
|
Long-Term Care | 1 | 2015 | 631 | 0.020 |
Why?
|
Up-Regulation | 1 | 2020 | 4117 | 0.020 |
Why?
|
Primary Prevention | 1 | 2018 | 1185 | 0.020 |
Why?
|
Vascular Endothelial Growth Factor A | 1 | 2022 | 3492 | 0.020 |
Why?
|
Vaccination | 1 | 2023 | 3370 | 0.020 |
Why?
|
Cell Adhesion Molecules | 1 | 2017 | 1602 | 0.020 |
Why?
|
Antiviral Agents | 1 | 2023 | 3037 | 0.020 |
Why?
|
Immunosuppressive Agents | 1 | 2023 | 4172 | 0.020 |
Why?
|
Norway | 1 | 2012 | 499 | 0.020 |
Why?
|
Health Promotion | 1 | 2022 | 2206 | 0.020 |
Why?
|
Retreatment | 1 | 2012 | 596 | 0.020 |
Why?
|
Metformin | 1 | 2018 | 906 | 0.020 |
Why?
|
Glucose | 1 | 2022 | 4345 | 0.020 |
Why?
|
Treatment Failure | 1 | 2016 | 2635 | 0.020 |
Why?
|
Enzyme-Linked Immunosorbent Assay | 1 | 2017 | 3798 | 0.020 |
Why?
|
Exercise Test | 1 | 2017 | 2127 | 0.020 |
Why?
|
Publishing | 1 | 2016 | 832 | 0.020 |
Why?
|
Creatine Kinase, MB Form | 1 | 2009 | 202 | 0.020 |
Why?
|
Curriculum | 1 | 2022 | 3739 | 0.020 |
Why?
|
Chronic Disease | 1 | 2023 | 9310 | 0.020 |
Why?
|
Atherectomy | 1 | 2008 | 42 | 0.020 |
Why?
|
Creatinine | 1 | 2014 | 1895 | 0.020 |
Why?
|
Intensive Care Units | 1 | 2021 | 3743 | 0.020 |
Why?
|
Phosphoproteins | 1 | 2017 | 2445 | 0.020 |
Why?
|
Logistic Models | 1 | 2022 | 13248 | 0.020 |
Why?
|
Longitudinal Studies | 1 | 2024 | 14599 | 0.020 |
Why?
|
Waist Circumference | 1 | 2011 | 933 | 0.020 |
Why?
|
Hypertension, Pulmonary | 1 | 2018 | 1582 | 0.020 |
Why?
|
Fractures, Bone | 1 | 2019 | 2045 | 0.020 |
Why?
|
Anthropometry | 1 | 2011 | 1338 | 0.020 |
Why?
|
United States Food and Drug Administration | 1 | 2015 | 1661 | 0.020 |
Why?
|
Bone Density | 1 | 2019 | 3548 | 0.020 |
Why?
|
Aortic Valve | 1 | 2016 | 1955 | 0.020 |
Why?
|
Pulmonary Embolism | 1 | 2020 | 2568 | 0.020 |
Why?
|
Clinical Competence | 1 | 2022 | 4790 | 0.020 |
Why?
|
Delivery of Health Care | 1 | 2023 | 5334 | 0.020 |
Why?
|
Mortality | 1 | 2017 | 2899 | 0.020 |
Why?
|
Odds Ratio | 1 | 2017 | 9644 | 0.010 |
Why?
|
Blood Pressure | 1 | 2019 | 8473 | 0.010 |
Why?
|
Transcription Factors | 1 | 2022 | 12116 | 0.010 |
Why?
|
Genetic Predisposition to Disease | 1 | 2024 | 17878 | 0.010 |
Why?
|
Infant, Newborn | 1 | 2022 | 26183 | 0.010 |
Why?
|
Hemodynamics | 1 | 2011 | 4160 | 0.010 |
Why?
|
Cross-Sectional Studies | 1 | 2022 | 26065 | 0.010 |
Why?
|
Massachusetts | 1 | 2014 | 8835 | 0.010 |
Why?
|
Signal Transduction | 1 | 2023 | 23415 | 0.010 |
Why?
|
Infant | 1 | 2022 | 36157 | 0.010 |
Why?
|
Preoperative Care | 1 | 2008 | 2242 | 0.010 |
Why?
|
Echocardiography | 1 | 2010 | 4987 | 0.010 |
Why?
|
Research Design | 1 | 2009 | 6174 | 0.010 |
Why?
|